GO
Loading...

Novartis AG

More

  • *Buffett's Berkshire, Novartis, Givaudan doing well. But good news is emerging now for those who prefer safer strategies: some of the best returns this year have come from stable stocks like billionaire Warren Buffett's holding company Berkshire Hathaway or Swiss toilet maker Geberit. "Investors are ready to invest on the equity market but under the condition...

  • European shares erase gains ahead of Fed minutes Wednesday, 19 Nov 2014 | 12:35 PM ET

    LONDON, Nov 19- European shares ended flat after hitting a seven-week high earlier on Wednesday, with investors trading cautiously ahead of minutes from the most recent Federal Reserve policy meeting. The market also faced pressure from a sharp decline in mining shares after China's iron ore futures dropped nearly 5 percent to a record low.

  • European shares edge lower ahead of Fed minutes Wednesday, 19 Nov 2014 | 11:24 AM ET

    LONDON, Nov 19- European shares edged lower from a seven-week high late on Wednesday, tracking a fall in U.S. equities, with investors trading cautiously ahead of minutes from the most recent Federal Reserve policy meeting. The market also came under pressure from a sharp decline in mining shares after China's iron ore futures dropped nearly 5 percent to a record...

  • European shares advance, Swiss index hits 9,000 Wednesday, 19 Nov 2014 | 8:48 AM ET

    LONDON, Nov 19- The pan-European FTSEurofirst 300 share index climbed to a seven-week high on Wednesday, helped by broker upgrades, and Switzerland's SMI equity index hit the 9,000 mark for the first time since late 2007.. Prudential rose 1.3 percent after Deutsche Bank increased its target price for the stock to 1,680 pence from 1,630 pence, Severn Trent was up...

  • European shares edge higher, Swiss index hits 7-year high Wednesday, 19 Nov 2014 | 6:09 AM ET

    LONDON, Nov 19- European shares turned positive in morning trading on Wednesday, helped by some encouraging broker upgrades, with Switzerland's SMI equity index hitting the 9,000- point mark for the first time since late 2007.. Prudential rose 1.1 percent to lead insurers after Deutsche Bank increased its target price for the stock to 1,680 pence from 1,630...

  • CHICAGO, Nov 17- An experimental heart failure medicine from Novartis that previously showed it reduced death and hospitalizations also curtailed worsening of symptoms, need for additional therapy and emergency room visits, adding to evidence that it will become the drug of choice once approved. The Novartis drug, expected to become a multibillion-dollar...

  • *Novartis already has Google contact lens, smart pill deals. LONDON, Nov 17- Talent spotters from Novartis AG, charged with bringing new ideas into the organisation, are casting their net beyond biotech into the wider pool of wearable, or even edible, technology. The Swiss group has already taken tentative steps, signing a deal with Google Inc in July to develop...

  • Actavis to spend $66 billion on Allergan Monday, 17 Nov 2014 | 9:32 AM ET

    Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products. Actavis and the company it outbid for Allergan, Valeant Pharmaceuticals, both have grown rapidly in recent years through multibillion dollar acquisitions of other drugmakers.

  • Nov 6- Hospira Inc reported a quarterly profit that handily beat analysts' estimates as the company raised prices and sold more of its injectable drugs. Hospira's shares rose as much as 9.2 percent to a more than three-year high of $57.99 on Thursday. Hospira challenged the decision but lost the case.

  • In September life-science company Calico, which was set up by Google last year to investigate the ageing process, joined with U.S. drugmaker AbbVie in committing an initial $250 million apiece to developing cures for age-related diseases. Away from the limelight, however, Switzerland's Novartis and Denmark's Novo Nordisk are already testing new roles for...

  • *Cipla says launched cheaper copy of Novartis drug in Delhi. *Cipla says Novartis not making enough drug for India. Cipla, India's fourth-largest drugmaker by revenue, said because there was an urgent but unmet need for the respiratory treatment in India it has started to sell a copy of the drug in Delhi priced at a fifth of the cost of Novartis's product.

  • UPDATE 1-Pfizer meningitis vaccine wins U.S. approval Wednesday, 29 Oct 2014 | 3:06 PM ET

    Oct 29- Pfizer Inc has won U.S. approval for its Trumenba vaccine against meningitis, a potentially deadly bacterial disease that has recently caused outbreaks on college campuses, the U.S. Food and Drug Administration said on Wednesday. It is the first approved U.S. vaccine that prevents invasive disease caused by the bacterium Neisseria meningitidis B, a...

  • Robust earnings spur European stocks higher Tuesday, 28 Oct 2014 | 8:27 AM ET

    *Sanofi share drop means over $10 bln market value wipeout. EDINBURGH, Oct 28- European shares rose in early trade on Tuesday, reversing the previous session's dip as better-than-expected results from a number of blue-chips including pharma group Novartis and bank UBS helped lift sentiment. While French pharma Sanofi and UK- listed Standard Chartered Bank...

  • Early Movers: DD, PFE, AET, TWTR, MSG, WMT & more Tuesday, 28 Oct 2014 | 8:07 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Novartis' precision M&A plan: CEO     Tuesday, 28 Oct 2014 | 6:12 AM ET

    We are focusing on three big divisions in the next five years - pharmaceuticals, generics and eye care., says Joe Jimenez, Novartis CEO, explaining how Novartis plans to benefit from partnering with other big pharma companies.

  • Novartis CEO on big pharma pipeline     Tuesday, 28 Oct 2014 | 6:11 AM ET

    We are focusing on innovation, says Joe Jimenez, Novartis CEO, discussing the company's growth prospects and the top three drugs driving sales.

  • LONDON, Oct 28- World stocks inched up and U.S. bond yields steadied after almost three weeks of gains on Tuesday with Federal Reserve policy setters expected to end six years of aggressive monetary stimulus. With the euro zone running into turbulence again and China's giant economy also struggling for pace, the prospect of a world without U.S. stimulus has...

  • Robust earnings help Europe stocks resume rally Tuesday, 28 Oct 2014 | 5:35 AM ET

    *FTSEurofirst 300 up 0.8 pct, Euro STOXX 50 up 0.9 pct. *Sanofi share drop represents $10 bln market value wipeout. PARIS, Oct 28- European shares rose in early trade on Tuesday, reversing the previous session's dip as better-than-expected results from a number of blue-chips including pharma group Novartis and bank UBS helped lift sentiment.

  • European shares rise early; Sanofi sinks Tuesday, 28 Oct 2014 | 4:08 AM ET

    PARIS, Oct 28- European shares rose in early trade on Tuesday, reversing the previous session's dip as better-than-expected results from a number of blue-chips including pharma group Novartis and bank UBS helped lift sentiment. At 0803 GMT, the FTSEurofirst 300 index of top European shares was up 0.6 percent at 1,313.05 points, with UBS up 1.9 percent and...

  • LONDON, Oct 27- Drugmakers sprinting to develop Ebola vaccines face a series of technical hurdles if they are to get millions of doses ready for use next year-- even assuming clinical trials are successful. The challenges include finding sufficient sterile capacity for filling and packaging finished vials, getting fast quality approvals from regulators, and...